Zhejiang Starry Pharm Co Ltd - Asset Resilience Ratio

Latest as of December 2023: 0.00%

Zhejiang Starry Pharm Co Ltd (603520) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Zhejiang Starry Pharm Co Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥23.15K
≈ $3.39K USD Cash + Short-term Investments

Total Assets

CN¥5.52 Billion
≈ $807.58 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2023)

This chart shows how Zhejiang Starry Pharm Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Zhejiang Starry Pharm Co Ltd.

Liquid Assets Composition Over Time

This chart breaks down Zhejiang Starry Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Zhejiang Starry Pharm Co Ltd to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥23.15K 0.0%
Total Liquid Assets CN¥23.15K 0.00%

Asset Resilience Insights

  • Limited Liquidity: Zhejiang Starry Pharm Co Ltd maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Zhejiang Starry Pharm Co Ltd Industry Peers by Asset Resilience Ratio

Compare Zhejiang Starry Pharm Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
Drug Manufacturers - Specialty & Generic 2.79%
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 2.51%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Harbin Pharmaceutical Group Co Ltd
SHG:600664
Drug Manufacturers - Specialty & Generic 0.97%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%

Annual Asset Resilience Ratio for Zhejiang Starry Pharm Co Ltd (2016–2023)

The table below shows the annual Asset Resilience Ratio data for Zhejiang Starry Pharm Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.00% CN¥23.15K
≈ $3.39K
CN¥5.52 Billion
≈ $807.23 Million
-0.02pp
2022-12-31 0.02% CN¥876.69K
≈ $128.29K
CN¥5.30 Billion
≈ $775.88 Million
-1.42pp
2021-12-31 1.43% CN¥70.16 Million
≈ $10.27 Million
CN¥4.90 Billion
≈ $716.35 Million
-1.53pp
2020-12-31 2.97% CN¥130.76 Million
≈ $19.13 Million
CN¥4.41 Billion
≈ $644.79 Million
+2.47pp
2017-12-31 0.50% CN¥10.00 Million
≈ $1.46 Million
CN¥2.01 Billion
≈ $294.62 Million
-3.20pp
2016-12-31 3.70% CN¥70.00 Million
≈ $10.24 Million
CN¥1.89 Billion
≈ $277.08 Million
--
pp = percentage points

About Zhejiang Starry Pharm Co Ltd

SHG:603520 China Drug Manufacturers - Specialty & Generic
Market Cap
$555.57 Million
CN¥3.80 Billion CNY
Market Cap Rank
#11880 Global
#3447 in China
Share Price
CN¥8.66
Change (1 day)
+0.58%
52-Week Range
CN¥8.00 - CN¥13.75
All Time High
CN¥651.92
About

Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more